Dexamethasone for Symptom Burden in Advanced Cancer Patients

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 5 versions Re-verified since Jun 6, 2024, no change to tracked fieldsv29-v33
  2. Start date: Feb 2006 to Feb 2, 2006v28
  3. Primary completion date: Feb 2021 to Feb 28, 2021
    • Study completion date: Feb 2023 to Feb 28, 2028
    v27
  4. Study completion date: Feb 2022 to Feb 2023v26
  5. Results first posted: Dec 21, 2021v25 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 160 to confirmed 132
    • Study completion date: Feb 2021 to Feb 2022
    • Secondary endpoints expanded, about 32 words
Show 23 earlier versionsHide 23 earlier versions
  1. Primary completion date: Feb 2020 to Feb 2021v24
  2. Study completion date: Feb 2020 to Feb 2021v23
  3. Re-verified, no change to tracked fieldsv22
  4. Primary and study completion dates: Feb 2019 to Feb 2020v21
  5. Primary completion date: Feb 2018 to Feb 2019
    • Study completion date: Feb 2019
    v20
  6. Primary completion date: Feb 2017 to Feb 2018v19
  7. Primary completion date: Feb 2015 to Feb 2017
    • Study sites revised (2)
    • Collaborators expanded, about 4 words
    v18
  8. Primary endpoint revised
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 6 words
    v17
  9. Primary completion date: Feb 2014 to Feb 2015v16
  10. Primary completion date: Feb 2013 to Feb 2014v15
  11. Re-verified, no change to tracked fieldsv14
  12. Primary completion date: Feb 2012 to Feb 2013
    • Study description revised
    v13
  13. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 125 to 160
    • Site details revised at 2 of 2 sites
    v12
  14. Primary completion date: Feb 2011 to Feb 2012
    • Study description shortened, about 127 words
    v11
  15. Study sites revised (2)v10
  16. Primary completion date: Feb 2010 to Feb 2011
    • Primary endpoint revised
    v9
  17. Eligibility criteria shortened, about 94 words
    • Study description shortened, about 14 words
    v8
  18. Primary completion date: Feb 2009 to Feb 2010
    • Primary endpoint revised
    • Study description expanded, about 40 words
    v7
  19. Primary endpoint revised
    • Study description revised
    • Eligibility criteria shortened, about 2 words
    v6
  20. Study description revisedv5
  21. Primary endpoint revised
    • Site contacts updated at 1 of 2 sites
    • Eligibility criteria expanded, about 2 words
    v4
  22. Primary endpoint revisedv3 Show 5 more changesShow less
    • Primary completion date: Feb 2009
    • Study completion date: Feb 2008 to not stated
    • Secondary endpoints shortened, about 48 words
    • Study description shortened, about 47 words
    • Study title expanded, about 1 word
  23. Study completion date: Feb 2008
    • Site details revised at 1 of 2 sites
    • Study arms: 0 to 2
    • Eligibility criteria shortened, about 4 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if dexamethasone can help to control symptoms such as fatigue, pain, nausea, weight loss, loss of appetite, sleep problems, and/or depression in patients with advanced cancer.
Trial Details
NCT Number NCT00489307
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: American Cancer Society, Inc.
Conditions
(from sponsor)		 Solid Tumors
Related terms Anorexia, Fatigue, Nausea, Pain
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov